Roberto Cavallaro

List of Publications by Year
in descending order

151	3,670	134610	182931
papers	citations	34 h-index	54 g-index

160	160	160	4609
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	On the Implementation of Computerized Adaptive Observations for Psychological Assessment. Assessment, 2022, 29, 225-241.	1.9	3
2	Theory of mind and stereotypic behavior promote daily functioning in patients with schizophrenia. Australian and New Zealand Journal of Psychiatry, 2022, 56, 818-827.	1.3	4
3	Sustained symptomatic remission in schizophrenia: Course and predictors from a two-year prospective study. Schizophrenia Research, 2022, 239, 34-41.	1.1	3
4	It is time to address language disorders in schizophrenia: A RCT on the efficacy of a novel training targeting the pragmatics of communication (PragmaCom). Journal of Communication Disorders, 2022, 97, 106196.	0.8	18
5	Obsessive-compulsive symptoms moderates the effects of cognitive functioning on quality of life in clozapine-treated schizophrenia. Psychiatry Research Communications, 2022, , 100043.	0.2	0
6	Get up! Functional mobility and metabolic syndrome in chronic schizophrenia: Effects on cognition and quality of life. Schizophrenia Research: Cognition, 2022, 28, 100245.	0.7	0
7	Cognitive dysfunction in schizophrenia: An expert group paper on the current state of the art. Schizophrenia Research: Cognition, 2022, 29, 100249.	0.7	23
8	Cognitive remediation in schizophrenia: What happens after 10 years?. Schizophrenia Research: Cognition, 2022, 29, 100251.	0.7	2
9	Modeling the interplay of age at onset and sex on cognition in schizophrenia. Asian Journal of Psychiatry, 2022, , 103202.	0.9	3
10	Can IQ moderate the response to cognitive remediation in people with schizophrenia?. Journal of Psychiatric Research, 2021, 133, 38-45.	1.5	12
11	Exploring the role of age as a moderator of cognitive remediation for people with schizophrenia. Schizophrenia Research, 2021, 228, 29-35.	1.1	11
12	Clozapine tolerability in Treatment Resistant Schizophrenia: exploring the role of sex. Psychiatry Research, 2021, 297, 113698.	1.7	10
13	Functional benefits of co-occurring autistic symptoms in schizophrenia is delimited by symptom severity. Journal of Psychiatric Research, 2021, 137, 48-54.	1.5	9
14	Disentangling Cognitive Heterogeneity in Psychotic Spectrum Disorders. Asian Journal of Psychiatry, 2021, 60, 102651.	0.9	0
15	Longitudinal course of cognition in schizophrenia: Does treatment resistance play a role?. Journal of Psychiatric Research, 2021, 141, 346-352.	1.5	9
16	Communicative-pragmatic abilities mediate the relationship between cognition and daily functioning in schizophrenia.. Neuropsychology, 2021, 35, 42-56.	1.0	15
17	Cognitive Remediation for Inpatients With Schizophrenia. Journal of Nervous and Mental Disease, 2021, 209, 76-81.	0.5	1
18	Factors affecting cognitive remediation outcome in schizophrenia: The role of treatment resistance. European Psychiatry, 2021, 64, S168-S168.	0.1	0

#	Article	IF	Citations
19	P.0771 Targeting quality of life in schizophrenia: the fil rouge between metabolic syndrome and anxiety. European Neuropsychopharmacology, 2021, 53, S562.	0.3	0
20	P.0781 Words toward recovery: analyzing speech determinants of quality of life in chronic schizophrenia. European Neuropsychopharmacology, 2021, 53, S570-S571.	0.3	0
21	P.0488 Treatment-resistance as a predictor of cognitive remediation outcome in schizophrenia. European Neuropsychopharmacology, 2021, 53, S359-S360.	0.3	1
22	The Influence of Premorbid Adjustment and Autistic Traits on Social Cognitive Dysfunction in Schizophrenia. Journal of the International Neuropsychological Society, 2020, 26, 276-285.	1.2	16
23	The association of autistic traits with Theory of Mind and its training efficacy in patients with schizophrenia. Schizophrenia Research: Cognition, 2020, 19, 100164.	0.7	6
24	M51. EFFICACY OF â€œPRAGMACOM TRAININGâ€•IN SCHIZOPHRENIA: A RCT ON A NOVEL PRAGMATIC INTERVENTION. Schizophrenia Bulletin, 2020, 46, S153-S153.	2.3	1
25	M202. SEX-RELATED DIFFERENCES IN CLOZAPINE SIDE EFFECTS IN PATIENTS WITH TREATMENT-RESISTANT SCHIZOPHRENIA. Schizophrenia Bulletin, 2020, 46, S213-S213.	2.3	1
26	S67. TREATMENT-RESISTANCE AFFECTS LONG-TERM COGNITIVE TRAJECTORIES IN SCHIZOPHRENIA: A LONGITUDINAL STUDY. Schizophrenia Bulletin, 2020, 46, S59-S59.	2.3	0
27	The role of agency in schizophrenia: A pilot study on gaze agency. Schizophrenia Research, 2020, 222, 465-466.	1.1	1
28	A leopard cannot change its spots: A novel pragmatic account of concretism in schizophrenia. Neuropsychologia, 2020, 139, 107332.	0.7	25
29	Stability and generalization of combined theory of mind and cognitive remediation interventions in schizophrenia: Follow-up results.. Psychiatric Rehabilitation Journal, 2020, 43, 140-148.	0.8	5
30	Genetic variability of glutamate reuptake: Effect on white matter integrity and working memory in schizophrenia. Schizophrenia Research, 2019, 208, 457-459.	1.1	3
31	Schizophrenia, cannabis use and Catechol-O-Methyltransferase (COMT): Modeling the interplay on cognition. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2019, 92, 363-368.	2.5	9
32	Daily Functioning in Schizophrenia. Journal of Nervous and Mental Disease, 2019, 207, 615-619.	0.5	4
33	From cognitive and clinical substrates to functional profiles: Disentangling heterogeneity in schizophrenia. Psychiatry Research, 2019, 271, 446-453.	1.7	17
34	The role of premorbid adjustment in schizophrenia: Focus on cognitive remediation outcome. Neuropsychological Rehabilitation, 2019, 29, 1611-1624.	1.0	11
35	Intellectual and cognitive profiles in patients affected by schizophrenia. Journal of Neuropsychology, 2019, 13, 589-602.	0.6	24
36	Exploring predictors of work competence in schizophrenia: The role of theory of mind. Neuropsychological Rehabilitation, 2019, 29, 691-703.	1.0	7

#	Article	IF	Citations
37	Cognitive Reserve Profiles in Chronic Schizophrenia: Effects on Theory of Mind Performance and Improvement after Training. Journal of the International Neuropsychological Society, 2018, 24, 563-571.	1.2	18
38	Visual and audio emotion processing training for outpatients with schizophrenia: an integrated multisensory approach. Neuropsychological Rehabilitation, 2018, 28, 1131-1144.	1.0	6
39	Integrated cognitive remediation and standard rehabilitation therapy in patients of schizophrenia: persistence after 5 years. Schizophrenia Research, 2018, 192, 335-339.	1.1	35
40	Sexually divergent effect of COMT Val/met genotype on subcortical volumes in schizophrenia. Brain Imaging and Behavior, 2018, 12, 829-836.	1.1	10
41	Achieving recovery in patients with schizophrenia through psychosocial interventions: <scp>A</scp> retrospective study. Psychiatry and Clinical Neurosciences, 2018, 72, 28-34.	1.0	20
42	Improving Cognition to Increase Treatment Efficacy in Schizophrenia: Effects of Metabolic Syndrome on Cognitive Remediation's Outcome. Frontiers in Psychiatry, 2018, 9, 647.	1.3	17
43	Dialectical Behavior Therapy Skills Training in Alcohol Dependence Treatment: Findings Based on an Open Trial. Substance Use and Misuse, 2018, 53, 2368-2385.	0.7	43
44	Exploring anxiety in schizophrenia: New light on a hidden figure. Psychiatry Research, 2018, 268, 312-316.	1.7	11
45	Neurobiology of cognitive remediation in schizophrenia: Effects of EAAT2 polymorphism. Schizophrenia Research, 2018, 202, 106-110.	1.1	12
46	Obesity influences white matter integrity in schizophrenia. Psychoneuroendocrinology, 2018, 97, 135-142.	1.3	26
47	Can patients with schizophrenia have good mentalizing skills? Disentangling heterogeneity of theory of mind.. Neuropsychology, 2018, 32, 746-753.	1.0	10
48	Exploring functioning in schizophrenia: Predictors of functional capacity and real-world behaviour. Psychiatry Research, 2017, 251, 118-124.	1.7	58
49	Is longer treatment better? A comparison study of 3 versus 6 months cognitive remediation in schizophrenia.. Neuropsychology, 2017, 31, 467-473.	1.0	12
50	Targeting anxiety to improve quality of life in patients with schizophrenia. European Psychiatry, 2017, 45, 129-135.	0.1	23
51	Cognitive Remediation and Functional Improvement in Schizophrenia: is it a Matter of Size?. European Psychiatry, 2017, 40, 26-32.	0.1	23
52	The COMT Val158Met polymorphism moderates the association between cognitive functions and white matter microstructure in schizophrenia. Psychiatric Genetics, 2016, 26, 193-202.	0.6	10
53	The communicative impairment as a core feature of schizophrenia: Frequency of pragmatic deficit, cognitive substrates, and relation with quality of life. Comprehensive Psychiatry, 2016, 71, 106-120.	1.5	108
54	ADDing a piece to the puzzle of cognition in schizophrenia. European Journal of Medical Genetics, 2016, 59, 26-31.	0.7	11

#	Article	IF	Citations
55	Adverse childhood experiences influence the detrimental effect of bipolar disorder and schizophrenia on cortico-limbic grey matter volumes. Journal of Affective Disorders, 2016, 189, 290-297.	2.0	41
56	Combined social cognitive and neurocognitive rehabilitation strategies in schizophrenia: neuropsychological and psychopathological influences on Theory of Mind improvement. Psychological Medicine, 2015, 45, 3147-3157.	2.7	34
57	COMT Val158Met and 5-HT1A-R -1019 C/G polymorphisms: effects on the negative symptom response to clozapine. Pharmacogenomics, 2015, 16, 35-44.	0.6	37
58	Detecting syntactic and semantic anomalies in schizophrenia. Neuropsychologia, 2015, 79, 147-157.	0.7	37
59	Abnormal cortico-limbic connectivity during emotional processing correlates with symptom severity in schizophrenia. European Psychiatry, 2015, 30, 590-597.	0.1	40
60	Genomics and epigenomics in novel schizophrenia drug discovery: translating animal models to clinical research and back. Expert Opinion on Drug Discovery, 2015, 10, 125-139.	2.5	15
61	Shared reduction of oscillatory natural frequencies in bipolar disorder, major depressive disorder and schizophrenia. Journal of Affective Disorders, 2015, 184, 111-115.	2.0	47
62	Sterol Regulatory Element Binding Transcription Factor-1 Gene Variation and Medication Load Influence White Matter Structure in Schizophrenia. Neuropsychobiology, 2015, 71, 112-119.	0.9	14
63	Combined Neurocognitive And Metacognitive Rehabilitation In Schizophrenia: Effects On Bias Against Disconfirmatory Evidence. European Psychiatry, 2015, 30, 615-621.	0.1	19
64	Adverse childhood experiences influence white matter microstructure in patients with schizophrenia. Psychiatry Research - Neuroimaging, 2015, 234, 35-43.	0.9	32
65	P1.i.029 Effect of catechol-O-methyltransferase polymorphism on subcortical volumes in schizophrenia. European Neuropsychopharmacology, 2015, 25, S316-S317.	0.3	0
66	COMT and STH polymorphisms interaction on cognition in schizophrenia. Neurological Sciences, 2015, 36, 215-220.	0.9	12
67	Consensus five factor PANSS for evaluation of clinical remission: effects on functioning and cognitive performances. Schizophrenia Research: Cognition, 2014, 1, 187-192.	0.7	9
68	COMT and 5-HT1A-receptor genotypes potentially affect executive functions improvement after cognitive remediation in schizophrenia. Health Psychology and Behavioral Medicine, 2014, 2, 509-516.	0.8	19
69	Exploring effects of EAAT polymorphisms on cognitive functions in schizophrenia. Pharmacogenomics, 2014, 15, 925-932.	0.6	25
70	SMARTS (Systematic Monitoring of Adverse events Related to TreatmentS): The development of a pragmatic patient-completed checklist to assess antipsychotic drug side effects. Therapeutic Advances in Psychopharmacology, 2014, 4, 15-21.	1.2	36
71	P.3.b.013 Disrupted effective connectivity of emotional circuitry in schizophrenia: a dynamic causal modeling study. European Neuropsychopharmacology, 2014, 24, S498-S499.	0.3	0
72	P.3.b.034 Interaction of EAAT2 genotype and clozapine on cognitive remediation outcome. European Neuropsychopharmacology, 2014, 24, S511.	0.3	0

#	Article	IF	Citations
73	Factors affecting cognitive remediation response in schizophrenia: The role of COMT gene and antipsychotic treatment. Psychiatry Research, 2014, 217, 9-14.	1.7	57
74	Effect of glutamate transporter EAAT2 gene variants and gray matter deficits on working memory in schizophrenia. European Psychiatry, 2014, 29, 219-225.	0.1	28
75	Flexible-dose oral paliperidone ER in non-acute schizophrenia previously unsuccessfully treated with oral risperidone. Clinical Practice (London, England), 2014, 11, 573-583.	0.1	1
76	Criteria for symptom remission revisited: a study of patients affected by schizophrenia and schizoaffective disorders. BMC Psychiatry, 2013, 13, 235.	1.1	20
77	Catechol-O-methyltransferase (COMT) genotype biases neural correlates of empathy and perceived personal distress in schizophrenia. Comprehensive Psychiatry, 2013, 54, 181-186.	1.5	16
78	P.3.b.029 Antipsychotics, metabolic syndrome and schizophrenia: investigating the role of SREBF polymorphisms. European Neuropsychopharmacology, 2013, 23, S446.	0.3	0
79	Theory of Mind intervention for outpatients with schizophrenia. Neuropsychological Rehabilitation, 2013, 23, 383-400.	1.0	47
80	The Reality Monitoring Deficit as a Common Neuropsychological Correlate of Schizophrenic and Affective Psychosis. Behavioral Sciences (Basel, Switzerland), 2013, 3, 244-252.	1.0	11
81	Long-term remission in schizophrenia and schizoaffective disorder: results from the risperidone long-acting injectable versus quetiapine relapse prevention trial (ConstaTRE). Therapeutic Advances in Psychopharmacology, 2013, 3, 191-199.	1.2	11
82	CogpackÂ®: prove di efficacia. , 2013, , 161-167.		0
83	Valutazioni del funzionamento cognitivo â€œtrasferibiliâ€•alla pratica clinica: le scale BACS e SCoRS. , 2013, , 59-68.		0
84	CogpackÂ®: presupposti, descrizione e metodi a confronto. , 2013, , 151-160.		0
85	S.09.02 Predicting cognitive remediation outcome with genes. European Neuropsychopharmacology, 2012, 22, S125-S126.	0.3	0
86	P.3.a.014 Exploring the effect of genetic variability of adducins on cognition in schizophrenia. European Neuropsychopharmacology, 2012, 22, S311-S312.	0.3	0
87	Saitohin polymorphism and executive dysfunction in schizophrenia. Neurological Sciences, 2012, 33, 1051-1056.	0.9	8
88	Factors involved in the level of functioning of patients with schizophrenia according to latent variable modeling. European Psychiatry, 2012, 27, 396-400.	0.1	24
89	A functional comparison of patients with schizophrenia between the North and South of Europe. European Psychiatry, 2012, 27, 442-444.	0.1	7
90	Self-awareness of cognitive functioning in schizophrenia: Patients and their relatives. Psychiatry Research, 2012, 198, 207-211.	1.7	25

#	Article	IF	Citations
91	Theory of mind and emotion processing training for patients with schizophrenia: Preliminary findings. Psychiatry Research, 2012, 198, 371-377.	1.7	62
92	Patterns of evidence integration in schizophrenia and delusion. Psychiatry Research, 2012, 200, 108-114.	1.7	24
93	Cognitive dysfunction and glutamate reuptake: Effect of EAAT2 polymorphism in schizophrenia. Neuroscience Letters, 2012, 522, 151-155.	1.0	53
94	9-OH risperidone response in risperidone poor responders: An open study of drug response concordance. Neurology Psychiatry and Brain Research, 2012, 18, 109-113.	2.0	2
95	Effect of 5-HT1A-receptor functional polymorphism on Theory of Mind performances in schizophrenia. Psychiatry Research, 2011, 188, 187-190.	1.7	23
96	P.3.a.016 Effects of catechol-O-methyltransferase Val108/158Met and Saitohin q7r polymorphisms on cognitive functions in schizophrenia. European Neuropsychopharmacology, 2011, 21, S462.	0.3	0
97	Premorbid Functioning and Treatment Response in Recent-Onset Schizophrenia. Journal of Clinical Psychopharmacology, 2011, 31, 75-81.	0.7	18
98	Emotional reactivity in chronic schizophrenia: structural and functional brain correlates and the influence of adverse childhood experiences. Psychological Medicine, 2011, 41, 509-519.	2.7	54
99	The comprehension of idiomatic expressions in schizophrenic patients. Neuropsychologia, 2010, 48, 1032-1040.	0.7	44
100	Temporal lobe grey matter volume in schizophrenia is associated with a genetic polymorphism influencing glycogen synthase kinase 3â€Î² activity. Genes, Brain and Behavior, 2010, 9, 365-371.	1.1	54
101	Computer-aided neurocognitive remediation in schizophrenia: Durability of rehabilitation outcomes in a follow-up study. Neuropsychological Rehabilitation, 2010, 20, 659-674.	1.0	33
102	EXECUTIVE DYSFUNCTION IN SCHIZOPHRENIA: POSSIBLE ROLE OF SAITOHIN GENE. Schizophrenia Research, 2010, 117, 217.	1.1	0
103	Management of physical health in patients with schizophrenia: international insights. European Psychiatry, 2010, 25, S37-S40.	0.1	16
104	HTTLPR functional polymorphism in schizophrenia: Executive functions vs. sustained attention dissociation. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2010, 34, 81-85.	2.5	31
105	Computer-aided neurocognitive remediation as an enhancing strategy for schizophrenia rehabilitation. Psychiatry Research, 2009, 169, 191-196.	1.7	83
106	Meeting report: The Emory Universityâ€“San Raffaele cognition satellite meeting. Schizophrenia Research, 2009, 113, 347-350.	1.1	0
107	Functional and structural brain correlates of theory of mind and empathy deficits in schizophrenia. Schizophrenia Research, 2009, 114, 154-160.	1.1	137
108	â€˜Theoryâ€™ of mind impairment in patients affected by schizophrenia and in their parents. Schizophrenia Research, 2009, 115, 278-285.	1.1	57

#	Article	IF	Citations
109	P.3.14 Association study of COMT Val108/158Met polymorphism and treatment response to haloperidol, risperidone and clozapine. European Neuropsychopharmacology, 2009, 19, S73-S74.	0.3	2
110	P.3.c.063 Effect of 5-HT1a and catechol-O-methyl-transferase gene polymorphisms on negative symptom response to clozapine. European Neuropsychopharmacology, 2009, 19, S546-S547.	0.3	0
111	Long-term Remission in Schizophrenia and Schizoaffective Disorder: Results from the Risperidone Long-acting Injectable Versus Quetiapine Relapse Prevention Trial (constatre). European Psychiatry, 2009, 24, .	0.1	1
112	The Brief Assessment of Cognition in Schizophrenia. Normative data for the Italian population. Neurological Sciences, 2008, 29, 85-92.	0.9	110
113	Psychopathological and neuropsychological correlates of source monitoring impairment in schizophrenia. Psychiatry Research, 2007, 150, 51-59.	1.7	42
114	Influence of catechol-O-methyltransferase Val158Met polymorphism on neuropsychological and functional outcomes of classical rehabilitation and cognitive remediation in schizophrenia. Neuroscience Letters, 2007, 417, 271-274.	1.0	90
115	The pharmacology and safety of paliperidone extended-release in the treatment of schizophrenia. Expert Opinion on Drug Safety, 2007, 6, 651-662.	1.0	40
116	Standardized remission criteria in schizophrenia. Acta Psychiatrica Scandinavica, 2006, 113, 91-95.	2.2	238
117	The effect of verbalization strategy on wisconsin card sorting test performance in schizophrenic patients receiving classical or atypical antipsychotics. BMC Psychiatry, 2006, 6, 3.	1.1	16
118	Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype. International Journal of Neuropsychopharmacology, 2005, 8, 411-425.	1.0	109
119	Cerebral D2 and 5-HT2 Receptor occupancy in Schizophrenic Patients Treated with Olanzapine Or Clozapine. Journal of Psychopharmacology, 2004, 18, 355-365.	2.0	37
120	Citalopram Concentrations and Response in Obsessive-Compulsive Disorder. CNS Drugs, 2004, 18, 329-335.	2.7	19
121	Genetic dissection of drug effects in clinical practice: CLOCK gene and clozapine-induced diurnal sleepiness. Neuroscience Letters, 2004, 367, 152-155.	1.0	13
122	Clozapine-Induced Hypersensitivity Myocarditis. Chest, 2004, 126, 1703-1705.	0.4	53
123	Tardive dyskinesia and DRD2, DRD3, DRD4, 5-HT2A variants in schizophrenia: an association study with repeated assessment. International Journal of Neuropsychopharmacology, 2004, 7, 489-493.	1.0	45
124	Cabergoline Treatment of Risperidone-Induced Hyperprolactinemia. Journal of Clinical Psychiatry, 2004, 65, 187-190.	1.1	56
125	Reply to "Cardiopulmonary Complications of Ergot-Derivative Dopamine Agonists". Journal of Clinical Psychiatry, 2004, 65, 1430.	1.1	1
126	Basal-corticofrontal circuits in schizophrenia and obsessive-compulsive disorder. Biological Psychiatry, 2003, 54, 437-443.	0.7	127

#	Article	IF	Citations
127	Obsessive compulsive disorder among idiopathic focal dystonia patients: an epidemiological and family study. Biological Psychiatry, 2002, 52, 356-361.	0.7	71
128	Pharmacogenetics of Tardive Dyskinesia Combined Analysis of 780 Patients Supports Association with Dopamine D3 Receptor Gene Ser9Gly Polymorphism. Neuropsychopharmacology, 2002, 27, 105-119.	2.8	217
129	Differential efficacy of risperidone versus haloperidol in psychopathological subtypes of subchronic schizophrenia. Human Psychopharmacology, 2001, 16, 439-448.	0.7	6
130	Olanzapine-induced neutropenia after clozapine-induced neutropenia. Lancet, The, 1999, 354, 567.	6.3	52
131	The sequential treatment approach to resistant schizophrenia with risperidone and clozapine: results of an open study with follow-up. Human Psychopharmacology, 1998, 13, 91-97.	0.7	6
132	A genetic study of Tardive Dyskinesia in an Italian population of chronic schizophrenics. Psychiatric Genetics, 1996, 6, 170.	0.6	5
133	A pilot, open study on the treatment of refractory schizophrenia with risperidone and clozapine. Human Psychopharmacology, 1995, 10, 231-234.	0.7	22
134	Antipsychotic-Induced Tardive Dyskinesia. CNS Drugs, 1995, 4, 278-293.	2.7	18
135	Genetic control of the metabolism of neuroleptics: implications for the management of therapeutic dosages and side effects. European Neuropsychopharmacology, 1994, 4, 376-377.	0.3	0
136	Vitamin E treatment of persistent tardive dyskinesia: a double-blind, placebo-controlled, cross-over study. European Neuropsychopharmacology, 1994, 4, 375.	0.3	1
137	Tolerance and withdrawal with zolpidem. Lancet, The, 1993, 342, 374-375.	6.3	59
138	Tardive Dyskinesia Outcomes: Clinical and Pharmacologic Correlates of Remission and Persistence. Neuropsychopharmacology, 1993, 8, 233-239.	2.8	43
139	Smooth pursuit eye movements and saccadic eye movements in patients with delusional disorder. American Journal of Psychiatry, 1993, 150, 1411-1414.	4.0	6
140	Rare presentation of tardive dyskinesia. American Journal of Psychiatry, 1992, 149, 1115-1115.	4.0	1
141	Prolactin concentrations after single and repeated oral doses of savoxepine in patients with chronic schizophrenia. European Neuropsychopharmacology, 1991, 1, 434-435.	0.3	0
142	Factors Affecting the Clinical Response to Haloperidol Therapy in Schizophrenia. Clinical Neuropharmacology, 1990, 13, S29-S34.	0.2	8
143	Prevalence and risk factors for tardive dyskinesia: a study in an Italian population of chronic schizophrenics. European Archives of Psychiatry and Neurological Sciences, 1990, 240, 9-12.	0.9	12
144	Pharmacokinetics and adverse effects of single doses of dothiepin in young and elderly subjects. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1990, 14, 163-170.	2.5	6

#	Article	IF	Citations
145	Hydroxyhaloperidol and Clinical Outcome in Schizophrenia. , 1989, 7, 263-268.		4
146	Plasma reduced haloperidol levels and clinical outcome in schizophrenia. Pharmacological Research Communications, 1988, 20, 18.	0.2	0
147	Reduced Haloperidol/Haloperidol ratio and clinical outcome in schizophrenia: Preliminary evidences. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1988, 12, IN3-694.	2.5	26
148	HALOPERIDOL METABOLISM AND ANTIPSYCHOTIC EFFECT IN SCHIZOPHRENIA. Lancet, The, 1987, 329, 814-815.	6.3	22
149	Antiprostatic effect of cimetidine in rats. Agents and Actions, 1987, 22, 197-201.	0.7	8
150	Communication in schizophrenia, between pragmatics, cognition, and social cognition. Linguistik Aktuell, 0, , 213-234.	0.5	7
151	Targeting the communicative impairment in schizophrenia with a neuropragmatic approach. Frontiers in Psychology, 0, 8, .	1.1	0